Astrid Ammendola

Statistics

Publications

Citations

291

H-Index

Active since

2009

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

University of Genoa

Heidelberg University

Istituti di Ricovero e Cura a Carattere Scientifico

Astrid Ammendola is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in medicine, oncology, and immunotherapy.

Publications per year

2009–2019

Publications

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

Michael Bitzer, Marius Horger, Edoardo G. Giannini et al. · Journal of Hepatology · 2016 · 138 citations

Medicine, Oncology, Pharmacotherapy +9

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler et al. · Journal for ImmunoTherapy of Cancer · 2019 · 85 citations · Full text

Medicine, Immunology, Oncology +17

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

David Carbone, Michael F. Sharpnack, Kai He et al. · Journal of Translational Medicine · 2018 · 28 citations · Full text

Life Sciences, Immunology, Oncology +17

Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study

Jan Walewski, Ewa Paszkiewicz‐Kozik, Gabriela Borsaru et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2018 · 25 citations

Medicine, Pharmacology, Immunotherapy +12

The peptide‐semicarbazone S‐2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells

Philipp Baumann, Karin Müller, Sonja Mandl–Weber et al. · British Journal of Haematology · 2009 · 15 citations

Medicine, Medicinal Chemistry, Pharmacology +14

1–5 of 5